Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of Saroglitazar Magnesium 2 mg and 4 mg in patients with NASH. This study will be initiated after obtaining the approvals of Institutional Ethics Committee/Institutional Review Board (IEC/IRB) and the local regulatory authority.


Clinical Trial Description

Patients clinically suspected of NASH will be invited for a screening programme for inclusion in the study. Patients will be screened according to the inclusion and exclusion criteria. Clinical evaluation will be conducted for baseline characteristics and anthropometry measurements such as body weight and height. After clinical evaluations, all baseline safety and efficacy parameters will be recorded as per Visit Schedule. All laboratory collections will be performed following overnight fasting (at least 8 hrs). Following confirmation of all clinical and laboratory inclusion and exclusion criteria, patients will continue into the screening period. During the screening period liver biopsy will be performed. However, if a biopsy was performed within 6 months the slides and biopsy material, or block, must be made available for baseline documentation. Such Patients, whose historical biopsy report is available, should not use medication suspected of having an effect on NASH from the 3 months prior to the screening. Liver biopsy will be performed to confirm the diagnosis of NASH and record a baseline NAFLD Activity Score. The histological evidence of NASH is defined as NAS ≥ 4 with a minimum score of 1 for all of its three components [steatosis, hepatocyte ballooning and lobular inflammation]. Following confirmation of inclusion/exclusion criteria and upon histological confirmation of NASH by liver biopsy, patients will be enrolled into the study. Eligible patients will be randomly assigned to receive Saroglitazar Magnesium 2 mg or 4 mg or placebo in a 2:2:1 ratio for 24 weeks. Upon completion of 24 weeks of treatment, liver biopsy will be performed and the NAFLD Activity Score recorded. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03863574
Study type Interventional
Source Zydus Therapeutics Inc.
Contact
Status Completed
Phase Phase 2
Start date June 12, 2019
Completion date October 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Completed NCT01695083 - Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Not yet recruiting NCT05605158 - Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis Phase 3
Completed NCT01761370 - Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH) N/A
Completed NCT03432377 - Coffee Consumption and NASH in the French Population.
Withdrawn NCT03864835 - NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal N/A
Completed NCT05357352 - Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Not yet recruiting NCT03803540 - Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis Phase 1
Completed NCT02395900 - The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Phase 2/Phase 3
Completed NCT01791959 - The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Phase 2/Phase 3
Recruiting NCT05821010 - Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT03734510 - The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study N/A
Recruiting NCT02721264 - Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis. N/A
Terminated NCT03883607 - Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT03377140 - The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT03377153 - The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease N/A
Active, not recruiting NCT04669158 - Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis Phase 1/Phase 2
Recruiting NCT06176079 - Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
Withdrawn NCT01384578 - Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis Phase 3